4 stocks likely to move big in Q4 '24 on mental illness readouts
We used our BPIQ platform to identify biopharma stocks likely to move big in the fourth quarter on mental illness readouts. We found 4 of them! See the table and text below for more details, which are likely to be a big or a suspected mover, based on implied volatility data.
$RVPH
Brilaroxazine/ Schizophrenia / Ph3 OLE ✔️
Brilaroxazine is a Serotonin/dopamine modulator (NCE) studied in multiple neuropsychiatric indications. Compelling topline data from Ph3 RECOVER-1 trial in Schizophrenia. Long-term safety and tolerability data from Ph3 OLE expected in Q4 '24.
Prior results📸
$CMPS
COMP360 (Psilocybin) / Treatment-Resistant Depression (TRD) / Ph3
COMP360 is a formulation of synthetic psilocybin. Completed a phase 2b study in TRD patients & showed clinically relevant improvement in depressive symptom. Top-line COMP005 Ph3 data upcoming in Q4 '24.
Prior results📸
$GHRS
GH001 (inhalable mebufotenin) /Treatment-Resistant Depression (TRD) / Ph2b
GH001 is formulated for mebufotenin administration via pulmonary inhalation. Completed two Ph1 clinical trials & a Ph1/2 trial in patients with TRD. Expects completion of Ph2b double-blind phase in Q3 '24 & topline data by Q4 '24 or Q1 '25.
Prior results 📸
$NMRA
Navacaprant (NMRA-140)/Major depressive disorder (MDD) / Ph3 ✔️
Navacaprant is a highly selective, novel kappa opioid receptor (KOR) antagonist in Ph3 development as a potential monotherapy treatment for MDD. It is designed to modulate the dopamine and processing pathways. Data from KOASTAL-1 study upcoming in Q4 '24.
Footnote: ✔️ Confirmed by implied volatility data.
Want to see all smid cap big movers in Q4 2024?
⏰ Limited Time Offer:
Become a BPIQ Elite member with our 🎉 End of Quarter Sale (50% Off) & get...
Big/Suspected Movers. We identify events that can drive significant price moves! 🚀
All catalysts, PDUFA dates and more! 🗓
🔐 Lock in the discount with a free trial!
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
Last updated 09/27/24 SK, JD & EJV
First published 09/25/24 SK, JD & EJV